COVID-19 induces a proinflammatory environment that is stronger in patients requiring
intensive care. The cytokine components of this environment may determine efficacy or …

COVID-19 is rapidly spreading contagious disease spreading across the world. Patients at
risk are elderly people and those with comorbidity. Early studies done on Chinese patients …

Clinically approved PARP inhibitors (PARPi) have a mild adverse effect profile and are well
tolerated as continuous daily oral therapy. We review the evidence that justifies the …

Poly (ADP-ribose) polymerase, member 14 (PARP14, alternatively named ARTD8, BAL2,
and COAST6) is an intracellular mono (ADP-ribosyl) transferase. PARP14 transfers a …

Poly (ADP-ribose) polymerase (PARP) superfamily members covalently link either a single
ADP-ribose (ADPR) or a chain of ADPR units to proteins using NAD as the source of ADPR …

Understanding the potential association between the poly (ADP-ribose) polymerase
member 14 (PARP14) and the severe acute respiratory syndrome coronavirus 2 (SARS-CoV …

Dysregulated host immune responses drive mortality in pneumonia and acute respiratory
distress syndrome (ARDS) caused by a wide range of infections. In coronavirus disease …

The clinical potential of PARP-1 inhibitors has been recognized> 10years ago, prompting
intensive research on their pharmacological application in several branches of medicine …

PARP-catalysed ADP-ribosylation (ADPr) is important in regulating various cellular
pathways. Until recently, PARP-dependent mono-ADP-ribosylation has been poorly …

The outbreak of Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in Wuhan,
China, in December 2019, and its global dissemination became the coronavirus disease …